Legacy Private Trust Co. lifted its position in McKesson Co. (NYSE:MCK – Free Report) by 1.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 15,518 shares of the company’s stock after buying an additional 150 shares during the period. Legacy Private Trust Co.’s holdings in McKesson were worth $8,844,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. Private Advisor Group LLC increased its holdings in shares of McKesson by 4.2% in the second quarter. Private Advisor Group LLC now owns 11,467 shares of the company’s stock valued at $6,697,000 after buying an additional 462 shares in the last quarter. Los Angeles Capital Management LLC boosted its position in shares of McKesson by 254.0% in the 2nd quarter. Los Angeles Capital Management LLC now owns 2,418 shares of the company’s stock valued at $1,412,000 after purchasing an additional 1,735 shares during the period. PFG Investments LLC purchased a new stake in shares of McKesson in the 2nd quarter valued at approximately $249,000. Prudential PLC boosted its stake in McKesson by 0.4% in the 2nd quarter. Prudential PLC now owns 14,704 shares of the company’s stock worth $8,588,000 after purchasing an additional 52 shares during the period. Finally, Wedbush Securities Inc. grew its position in McKesson by 1.9% during the 2nd quarter. Wedbush Securities Inc. now owns 1,680 shares of the company’s stock worth $981,000 after purchasing an additional 32 shares in the last quarter. Institutional investors and hedge funds own 85.07% of the company’s stock.
Insider Activity at McKesson
In related news, EVP Leann B. Smith sold 579 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $602.81, for a total value of $349,026.99. Following the completion of the transaction, the executive vice president now directly owns 1,443 shares of the company’s stock, valued at $869,854.83. This trade represents a 28.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.11% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
Get Our Latest Stock Report on MCK
McKesson Price Performance
MCK traded up $4.36 on Wednesday, hitting $589.60. The company had a trading volume of 526,011 shares, compared to its average volume of 619,114. The stock has a market cap of $74.84 billion, a price-to-earnings ratio of 30.53, a price-to-earnings-growth ratio of 1.25 and a beta of 0.49. The company’s fifty day moving average price is $587.85 and its 200 day moving average price is $561.25. McKesson Co. has a 1-year low of $464.42 and a 1-year high of $637.51.
McKesson (NYSE:MCK – Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $7.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.88 by $0.19. The business had revenue of $93.65 billion during the quarter, compared to the consensus estimate of $89.33 billion. McKesson had a net margin of 0.77% and a negative return on equity of 207.50%. McKesson’s quarterly revenue was up 21.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.23 EPS. On average, sell-side analysts forecast that McKesson Co. will post 32.73 EPS for the current year.
McKesson Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, January 2nd. Investors of record on Monday, December 2nd were given a dividend of $0.71 per share. The ex-dividend date of this dividend was Monday, December 2nd. This represents a $2.84 annualized dividend and a dividend yield of 0.48%. McKesson’s dividend payout ratio is presently 14.71%.
McKesson Company Profile
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
Recommended Stories
- Five stocks we like better than McKesson
- What is the Nasdaq? Complete Overview with History
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Co. (NYSE:MCK – Free Report).
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.